Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069356 | 0.78 | SMN1; SMN2 (0.42) | PTGDR2POLBSMN1; SMN2PPARDALDH1A1 | |
| SCHEMBL2820783 | 0.77 | PPARD (0.59) | PTGDR2PPARD | |
| SCHEMBL5379717 | 0.76 | L3MBTL1 (0.63) | PTGDR2L3MBTL1POLBSMN1; SMN2GLA | |
| SCHEMBL22771505 | 0.76 | ALDH1A1 (0.37) | L3MBTL1POLBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2059383 | 0.72 | POLB (0.58) | PTGDR2L3MBTL1POLBSMN1; SMN2GLA | |
| SCHEMBL6746949 | 0.70 | L3MBTL1 (0.56) | PTGDR2L3MBTL1POLBSMN1; SMN2GLA | |
| SCHEMBL9346863 | 0.70 | L3MBTL1 (0.59) | PTGDR2L3MBTL1POLBSMN1; SMN2GLA | |
| SCHEMBL1887192 | 0.69 | KMT2A (0.61) | PTGDR2L3MBTL1POLBSMN1; SMN2GLA | |
| SCHEMBL29040313 | 0.69 | L3MBTL1 (0.54) | PTGDR2L3MBTL1POLBSMN1; SMN2GLA | |
| SCHEMBL7654284 | 0.68 | L3MBTL1 (0.55) | PTGDR2L3MBTL1POLBSMN1; SMN2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745003-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20090209588-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209588-A1 | Novel compounds, their preparation and use | PPARG, PPARD, GPR119 | PTGDR2 492/4885L3MBTL1 4656/4885POLB 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.